India’s Leading Pharmaceutical Company

If you have ever taken an over the counter allergy medication, an oral contraceptive, a generic sleep aid, or any of many, many other pharmaceutical products, you have definitely seen and used pharmaceutical blister packaging.

Pharmaceutical blister packaging consists of two main parts: a plastic front with individual pill pockets molded into it, and a flat piece of backing, likely made of some type of cardboard or foil.

Each pill rests in its own individual pocket, held between the plastic bubble and the foil or cardboard backing, and separated from the rest of the pills.

If you have ever taken medication that came in pharmaceutical blister packaging (and you almost certainly have if you live in the United States), you may have noticed that it can take some effort to get your pill out of its pocket.

You may have even wondered why a company would choose to use such involved packaging.

Well, there are actually multiple reasons pharmaceutical blister packaging is so popular.

Divis Laboratories Pvt Ltd Divis Labs is one of the Best Pharma Companies in Hyderabad, India in Manufacturing API (Active Pharmaceutical Ingredients), Nutraceutical, Naproxen, Gabapentin, and Dextromethorphan.Divis has been established for more than 28 years in Hyderabad and currently has 2 manufacturing units and 11,000 highly trained professionals.

And also setting up a manufacturing plant at Kakinada.Divi’s manufacturing facilities have undergone several audits by Global Regulatory Authorities, various Big Pharma/Multi-National Companies, Statutory Authorities, and Global Environmental, Health and Safety teams.

Divi’s specially provides the global pharmaceutical industry with the following reliable, cGMP quality, value-driven solutions for the below-mentioned products:Divis has been hailed as one of the Top Pharmaceutical Companies in India and acknowledged industry leader in Environment, Health, and Safety.

It has quality testing and validation labs.are fitted with state-of-the-art analytical equipment and testing facilities.Divi’s continues to be a global leader in Large Volume Generic APIs.

The product list includes a very selective 30 APIs that are manufactured commercially in 10’s to 100’s/1000’s of Tonnes each year and continues to be the largest API manufacturer in the world.Divi’s has achieved this leadership position because of various factors such as backward integration to basic starting materials, dedicated production blocks with large batch sizes and significant capacity creation ahead of time.

Can Pharmaceutical Engineering provide solutions for the challenges on the horizon?

What are the challenges that we will have to face in the years ahead?

The drug approval procedure also requires a lot of money and time.

Outsourcing helps you produce and commercialize your products without compromising with quality.

Also they help you lower your R budget which can lead to cheaper production.This can result in better product quality and also lower costChallenges on the Distribution: Now-a-days it has become very necessary for us to keep pace with the consumer demand.

Challenges on the Reservation/Installation front: A relatively new phenomenon among the medical world is the reserve of plants and other manufacturing houses to build facilities to manufacture drugs.

Global Research Institute of Pharmacy (GRIP) is amongst the top pharmacy colleges in Haryana.

The b pharmacy college in Haryana and d pharmacy college provides d pharma course and b pharma Haryana.

The global gastrointestinal therapeutics market size is expected to reach USD 65.1 billion by 2025, according to a new report by Grand View Research, Inc., registering a 6.6% CAGR during the forecast period.

Growing geriatric population prone to gastrointestinal indications is one of the key factors anticipated to contribute to market growth.

According to a report by WHO, colon cancer caused nearly 694,000 deaths in 2014.Growing geriatric population, especially in emerging economies, is expected to drive market growth over the coming years.

Furthermore, initiatives undertaken by the Centers for Disease Control and Prevention (CDC) to promote cancer screening nationwide is expected to boost market growth over the forecast period.

The Division of Cancer Prevention and Control (DCPC) supports National Colorectal Cancer Action Campaign (NCCCP) and provides funds to aid research studies and implement strategies to control colorectal cancer.

This increase in initiatives for screening is expected to fuel sales of therapeutics and present lucrative growth opportunities to the market.Further key findings from the report suggest:Based on product type, the branded drugs segment dominated in 2016 owing to high potency drugs such as biologics and proton pump inhibitors.